Photodynamic Therapy Market By Product (Photosensitizers, Porphyrin Derivative PD, Aminolevulinic Acid ALA), By Application (Cancer, Psoriasis, Acne, Others), By End User (Hospitals, Cosmetics & Dermatology Clinics, Cancer Treatment Centers, Others), By Devices (Disposable Fiber Optic Light Delivery Devices DFOLDD, Diode Lasers), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032

Report Overview

Photodynamic Therapy Market size is expected to be worth around USD 2.91 Bn by 2032 from USD 1.29 Bn in 2022, growing at a CAGR of 8.5% during the forecast period from 2023 to 2032.

The Photodynamic Therapy (PDT) market is experiencing robust growth, driven by the rising prevalence of skin cancer and a growing demand for effective treatment options for skin diseases. PDT, originally developed for cancer treatment, has gained momentum as an attractive option, especially for skin-related conditions. The prevalence of skin cancer, alongside the increasing need for breast cancer drugs and management of infectious diseases, has led to a surge in PDT adoption.

PDT involves administration of a photosensitizing drug which accumulates in the target cells. When the cells are exposed to light of a specific wavelength, the photosensitizer absorbs the light energy and produces reactive oxygen species which induce localized cell death and tissue destruction. Compared to traditional therapies, PDT offers greater selectivity and fewer side effects as the cytotoxic effect occurs only in illuminated areas.

PDT is approved for use in several indications including actinic keratosis, esophageal cancer, non-small cell lung cancer and certain skin conditions. Researchers are also evaluating PDT for applications in COVID-19, antimicrobial resistance, ophthalmic disorders, and more. Key players in the PDT market include Thermo Fisher Scientific, Bausch Health Companies Inc., and STEBA Biotech.

Recent developments that are expanding PDT applications and adoption include new photosensitizers with improved target cell selectivity and efficacy, novel delivery systems for better photosensitizer targeting, and clinical research into new indications. For example, in August 2022, Asieris Pharmaceuticals completed enrollment in a Phase III trial of its novel PDT agent Cevira for treating cervical precancerous lesions.

The future outlook for the PDT market is positive, driven by rising cancer prevalence, new product approvals, expanded applications, and technological improvements. Key trends that will further catalyze market growth are combination therapies, nanoparticle delivery systems, and increasing R&D into new photosensitizers and light sources. With its versatility, safety advantages, and continued innovation, PDT is positioned to become an increasingly valuable therapeutic option.

Driving factors

Increasing malignancy and chronic disease prevalence

One of the factors fueling the growth of the Photodynamic Therapy Market is the escalating incidence of cancer and chronic diseases. Photodynamic therapy has emerged as a viable option for patients as a result of their need for effective and non-invasive treatment methods. This therapy, which targets cancer cells and other diseased tissues with light, is increasing popularity due to its efficacy.

Increasing understanding of PDT

Increasing recognition of photodynamic therapy as a noninvasive treatment option contributes to market expansion. As more people become aware of this therapy, demand is likely to increase, leading to a rise in the number of providers offering photodynamic therapy (PDT). This will further stimulate the expansion of the market.

Innovations in technology

Innovations in PDT technology, such as improved light sources and photosensitizers, are propelling market expansion. These developments are enhancing the efficacy and efficiency of photodynamic therapy, thereby promoting its increased use. This enhanced adoption is anticipated to contribute to market expansion.

Regulatory updates and the emergence of new technologies

Regulatory updates and emerging technologies, such as artificial intelligence and robotics, may have a substantial effect on the Photodynamic Therapy Market. It is essential to monitor regulatory changes, as they may have an effect on the market. The potential for emerging technologies to make photodynamic therapy (PDT) more effective and efficient could increase demand for the treatment, propelling market expansion.

Potential disruptors

Potential market disruptors such as new entrants, changes in reimbursement policies, and unanticipated shifts in consumer behaviour could have an effect on the Photodynamic Therapy Market's competitive landscape. These factors may have an impact on market growth and must be monitored to assure a sustainable PDT market.

Restraining Factors

Expensiveness Linked to Photodynamic Therapy

Cost is one of the main drawbacks of PDT. PDT is relatively costly in comparison to other medical interventions. Several factors contribute to the high cost of photodynamic therapy (PDT), including the cost of apparatus, the cost of the photosensitizer, and the cost of the light source. In addition, PDT frequently necessitates multiple sessions, which can increase the total cost of treatment.

Patients may be dissuaded from pursuing PDT due to its high cost, particularly in regions where healthcare is already expensive. In addition, the costly cost of PDT can hinder its adoption in low-income countries. To solve this issue, industry participants must reduce the cost of PDT through research and development and the adoption of advanced manufacturing techniques.

Limited Access to Qualified Personnel for Photodynamic Therapy

The lack of qualified professionals, particularly in developing nations, is another factor preventing the widespread adoption of PDT. To perform PDT accurately and safely, a team of competent professionals, including physicians, nurses, and technicians, is required.

The limited availability of qualified professionals can result in treatment delays, increased costs, and substandard care. Industry participants and policymakers must resolve this problem by investing in PDT-training programmes for healthcare professionals. Educational institutions can play an important role in preparing the next generation of PDT-trained healthcare professionals.

Certain nations have stringent regulations governing the use of photodynamic therapy.

In many nations around the world, the use of PDT is subject to regulations. These regulations seek to ensure the safety and effectiveness of PDT and prevent its misuse and abuse. However, these regulations may be viewed as restrictive by some industry participants, thereby impeding market expansion.

By harmonising the regulatory frameworks regulating PDT globally, the adoption of PDT technology can be expedited. In addition, industry participants can collaborate closely with regulatory bodies to update the regulations and ensure that they reflect the most recent scientific developments in the field. This strategy will not only increase the adoption of PDT, but also guarantee its safety and effectiveness.

Adverse Repercussions of Photodynamic Therapy

As with all medical interventions, PDT has side effects. Pain, swelling, and redness are the most prevalent negative effects of PDT. In certain instances, PDT can result in scarring, burning, and other complications. These adverse effects may deter patients from undergoing PDT therapy.

The industry must develop photosensitizers that are both safe and efficacious in order to enhance the safety profile of photodynamic therapy (PDT). In addition, healthcare professionals must educate patients on the potential side effects of photodynamic therapy (PDT), the benefits of the treatment, and how to manage potential side effects.

By Product Analysis

The market for Photodynamic Therapy (PDT) has been divided into numerous product categories, including photosensitizers, light sources, and others. Among these, photosensitizers hold a significant share of the market. Photosensitizers are molecules that become active when exposed to a specific wavelength of light, thereby initiating a chemical reaction that can kill malignant cells.

This has resulted in an increase in demand for the photosensitizer market segment as consumers become increasingly aware of PDT's advantages. Patients are avoiding conventional chemotherapy in favour of less invasive and effective remedies such as photodynamic therapy (PDT). This change in consumer behaviour is fueling the increase in popularity of photosensitizers.

Due to its efficacy, convenience, and minimal adverse effects, the photosensitizer segment of the PDT market is anticipated to record the highest growth rate over the coming years. Also contributing to the prevalence of photosensitizers are their simplified administration and shorter treatment duration.

By Application Analysis

According to the applications, the PDT market has been segmented, with cancer treatment constituting the largest segment. Cancer segment was leading the photodynamic therapy market. PDT is a clinically proved and effective treatment for a variety of cancers, including those of the skin, lung, brain, prostate, and bladder.

Consumers are becoming increasingly aware of the efficacy of PDT as a treatment option for cancer. This has resulted in PDT becoming the favoured cancer treatment method. Patients value the minimally invasive nature of PDT as well as its minimal adverse effects.

Due to the rising incidence of cancer and the high efficacy of PDT as a treatment option, the cancer treatment segment is anticipated to record the highest growth rate. Additionally, the increasing demand for minimally invasive techniques is fueling the growth of the cancer treatment market.

By End User Analysis

Hospitals dominate the market for photodynamic therapy (PDT) because they are the primary healthcare facilities that offer PDT treatments. Because PDT requires specialised apparatus and trained medical personnel, hospitals are the primary users of this technology.

Due to the availability of specialised equipment and trained personnel, hospitals are preferred by patients over clinics. Additionally, hospitals are investing more in PDT technology to provide patients with a variety of treatment options.

Due to the rising demand for advanced treatment options and the rising incidence of malignancies, it is anticipated that the hospitals segment will record the highest growth rate.

Key Market Segments

By Product

• Photosensitizers
• Porphyrin Derivative PD
  • Hematoporphyrin Derivative HpD
  • Benzoporphyrin Derivative BPD
  • Texaphyrins
  • Others
• Aminolevulinic Acid ALA
• Chlorines
• Others

By Application

• Cancer
• • Basal Cell Carcinoma
  • Non-small Cell Lung Cancer
  • Head & Neck Cancer
  • Others
• Actinic Keratosis AK
• Psoriasis
• Acne
• Others

By End User

• Hospitals
• Cosmetics & Dermatology Clinics
• Cancer Treatment Centers
• Others

By Devices

• Disposable Fiber Optic Light Delivery Devices DFOLDD
• Diode Lasers

Growth Opportunity

Escalating Demand for Combination Treatments Involving Photodynamic Therapy

Combination therapy entails the concurrent use of PDT and conventional therapies including chemotherapy, radiation therapy, and immunotherapy. In the treatment of various malignancies, including lung, prostate, and breast cancer, the combination of PDT with these therapies has demonstrated increased efficacy. The synergistic effect of PDT with these cancer treatments can lead to lower doses of chemotherapy medications and the avoidance of radiation exposure while maintaining high levels of cancer treatment efficacy. This has resulted in a growing demand for combination therapy utilising PDT, which is anticipated to fuel the PDT market's expansion.

Expanding use of photodynamic therapy in the treatment of non-malignant diseases.

PDT has shown promise in the treatment of non-oncological maladies such as acne, psoriasis, and age-related macular degeneration, in addition to cancer. It has been demonstrated that PDT is effective at reducing the inflammation associated with these diseases, resulting in improved outcomes. As more research is conducted on the efficacy of PDT for non-oncological diseases, it is anticipated that the use of PDT will continue to increase, thereby contributing to the expansion of the PDT market.

Creation of innovative photosensitizers and light sources

Development of novel photosensitizers and light sources is crucial to the success of PDT. The development of new photosensitizers with greater specificity and selectivity for cancer cells, as well as the creation of light sources that can penetrate deeper into tissue to activate the photosensitizer, are anticipated to propel the market for photodynamic therapy (PDT). Several photosensitizers for the treatment of various types of cancer are presently in development, and the market is expected to experience a rapid influx of new photosensitizers in the near future.

Increasing photodynamic therapy adoption in emerging economies

With the increasing prevalence of cancer cases and other maladies in emerging economies, there has been a rise in the use of photodynamic therapy (PDT) in these areas. In emerging economies, the availability of low-cost PDT technologies and the increase in the number of healthcare facilities offering PDT treatments are anticipated to drive the growth of the PDT market. In the future years, China, India, and Brazil are anticipated to experience significant market expansion.

Latest Trends

Creation of innovative new photosensitizers and light sources

Photosensitizers and light sources play a crucial role in photodynamic therapy's efficacy and safety. In the market for photodynamic therapy, the development of novel photosensitizers and light sources has been a primary focus of research. Researchers are investigating safer, more effective photosensitizers and light sources with fewer adverse effects.

Consequently, the market has witnessed an increase in the availability of new photosensitizers and light sources, leading to the development of novel photodynamic therapy treatments for various diseases and disorders.

Increasing use of photodynamic therapy in combination therapy

Combination therapy employing photodynamic therapy has grown in prominence in recent years due to its efficacy in treating a variety of diseases and disorders. Researchers have discovered that combining photodynamic therapy with other treatment modalities, such as chemotherapy, radiotherapy, and immunotherapy, can improve clinical outcomes.

It has been discovered that combination therapy increases the efficacy of photodynamic therapy, reduces the dosages of other treatments, and minimises adverse effects. For the treatment of malignancies, psoriasis, and acne, the market has witnessed an increase in the adoption of combination therapies employing photodynamic therapy.

Growing emphasis on research and development to explore novel photodynamic therapy applications

Researchers are continually investigating novel photodynamic therapy applications. Researchers are investigating the treatment's efficacy in treating additional diseases and disorders, as it has demonstrated efficacy in treating a variety of diseases and disorders. The market has witnessed a greater emphasis on research and development to investigate new applications of photodynamic therapy, resulting in the creation of new treatment options for a variety of diseases and disorders. The increasing emphasis on research and development in the market for photodynamic therapy has led to a surge in investments that are anticipated to drive market growth.

Increase in the number of partnerships and collaborations

There has been a rise in the number of partnerships and collaborations among the market's major participants. The increase in market partnerships and collaborations has resulted in the exchange of knowledge, resources, and technology, which has led to the development of more effective treatments for a variety of diseases and disorders. Partnerships and collaborations have enabled key actors to increase their market presence, develop new products, and improve patient care. In the coming years, market expansion is anticipated to be driven by an increase in partnerships and collaborations among key market participants.

Regional Analysis

North America currently leads the global photodynamic therapy (PDT) market, dominating it with an unparalleled presence. PDT is an advanced medical treatment using light-sensitive drugs to attack cancer cells and treat various medical conditions, and its market is flourishing thanks to various factors: an advanced healthcare infrastructure, extensive research and development activities and higher adoption of innovative medical technologies which makes North America an ideal location for this innovative therapy; all these elements combined have propelled North America to the top spot of this global PDT market.

North America dominates the PDT market due to its robust financial investments in healthcare research and technology. Furthermore, its numerous world-renowned medical research institutions and academic centers help advance PDT. An aging population also creates demand for effective cancer treatments such as PDT. Its favorable reimbursement policies and regulatory framework also play a pivotal role in its expansion.

Key Regions and Countries

North America

• US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of Asia Pacific

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

The market for PDT is highly competitive, with several key companies vying for a significant share of the market. Allergan, Plc is one of the major players, with its diverse range of products, including Photofrin and Visudyne, which have been approved by the US FDA for treating certain types of cancer and age-related macular degeneration, respectively.

Galderma, S.A. is another significant player in the PDT market, offering Ameluz gel, a revolutionary treatment for actinic keratosis, a type of skin cancer. The Ameluz gel has received regulatory approvals from renowned agencies like the FDA and the European Medicines Agency, attesting to its effectiveness and reliability in the field of PDT.

Biofrontera AG is another noteworthy player in the market, offering a range of products like Belixos and Ameluz, which have garnered attention for their innovative and promising approach to PDT. Quest PharmaTech, Inc. has also established its presence in the market with its unique Photodynamic Therapy for Cancer Treatment (PCRT) technology, providing an alternative and promising treatment modality for cancer patients.

The emergence of new players like Photocure ASA (Hexvix and Cysview) and Hologic, Inc. holds tremendous promise for the development of PDT, providing new products and techniques to further advance the field. With a few dominant players holding significant market share, and new entrants constantly entering the market, the PDT market is highly competitive, making it an exciting and dynamic field to watch.

Top Key Players in Photodynamic Therapy Market

• Biofrontera AG
• Theralase Technologies Inc.
• Lumibird
• Quest PharmaTech Inc.
• Modulight Inc.
• Galderma S.A.
• Sun Pharmaceutical Industries Ltd.
• SUS Advancing Technology Co. Ltd.
• Bausch Health Co. Inc.
• Biolase Inc.
• Pinnacle Biologics Inc.

Recent Development

• New photosensitizers with improved properties, such as increased selectivity and efficacy, are being developed in 2023. Additionally, new delivery systems are being explored to improve the targeting and biodistribution of photosensitizers.
• PDT is being investigated for a growing range of applications, including cancer, infectious diseases, and dermatological conditions in 2023. For example, PDT is being studied as a potential treatment for COVID-19 and other viral infections.
• In August 2022, Asieris Pharmaceuticals announced the completion of enrollment in its multinational Phase III clinical trial of Cevira (APRICITY), a novel non-surgical treatment for cervical high-grade squamous intraepithelial lesions (HSIL). Cevira is a breakthrough photodynamic drug-device combination product that works by accumulating a photosensitizer in the target cells.
• In 2021, a research study demonstrated the potential use of photodynamic therapy (PDT) in the treatment of pancreatic cancer, offering new treatment options for this difficult disease.

Report Scope: